Consensus Tarsus Pharmaceuticals, Inc.

Stocks

TARS

US87650L1035

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 00:00:00 21/07/2026 +04			5-day change	1st Jan Change
56.25 ^USD	-6.02%		-3.39%	-30.02%

07-16	RxSight Names Aziz Mottiwala as CEO	MT
07-14	Tarsus Pharmaceuticals, Inc. Announces Management Changes, Effective July 13, 2026	CI

Evolution of the Average Target: Tarsus Pharmaceuticals, Inc.

Evolution of the Target Price: Tarsus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Tarsus Pharmaceuticals, Inc.

5be116a4a6de00f4e43effb00904.e2HP7EJzELbqqNJBIuth8J-qhW6ZSf-DDGIWGY-lsF0.CVepmjE4Z9yu0eAFV7IuiPv-qD7APJfoWAtJaOr9gA4_JJDYNCNex9jBhw~53960c859e368bc072ee0323c15870ac

Analysts' recommendations: Tarsus Pharmaceuticals, Inc.

04-24	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating	MT
04-23	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $100 From $101, Keeps Outperform Rating	MT
03-26	Mizuho Lifts Price Target on Tarsus Pharmaceuticals to $101 From $100, Keeps Outperform Rating	MT
02-25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating	MT
11-20	Mizuho Initiates Tarsus Pharmaceuticals at Outperform With $100 Price Target	MT
09/10/25	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
09/10/25	BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80	MT
07/08/25	Tarsus Pharmaceuticals Q2 revenue beats expectations	RE
02/06/25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating	MT
03/02/25	BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74	MT
22/01/25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $72 From $65, Keeps Outperform Rating	MT
14/11/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	MT
09/08/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating	MT
09/05/24	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT
29/02/24	Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating	MT
28/02/24	Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating	MT
20/11/23	Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target	MT
10/11/23	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $42, Keeps Buy Rating	MT
11/09/23	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $49 From $46, Maintains Buy Rating	MT
11/08/23	HC Wainwright Adjusts Tarsus Pharmaceuticals Price Target to $42 From $50, Maintains Buy Rating	MT
26/07/23	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $44, Maintains Buy Rating	MT
18/07/23	William Blair Initiates Tarsus Pharmaceuticals at Outperform Rating	MT
26/06/23	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $44 From $40, Keeps Buy Rating	MT
16/06/23	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $42 From $40, Maintains Buy Rating	MT
18/05/23	Guggenheim Initiates Coverage on Tarsus Pharmaceuticals With Buy Rating, $40 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TARSUS PHARMACEUTICALS, INC.					+57.99%
	REGENERON PHARMACEUTICALS, INC.					+21.06%
	UCB					+20.33%
	SAMSUNG BIOLOGICS CO.,LTD.					+47%
	CSL LIMITED					+12.23%
	BIOGEN INC.					+9.86%
	MODERNA, INC.					-21.93%
	INCYTE CORPORATION					-2.93%
	INNOVENT BIOLOGICS, INC.					+32.1%
	SWEDISH ORPHAN BIOVITRUM AB					+7.12%
	Average					+18.28%
	Weighted average by Cap.					+17.50%